Robert W. Baird Issues Positive Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST) had its target price hoisted by research analysts at Robert W. Baird from $46.00 to $48.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 15.86% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Barclays cut their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Leerink Partners boosted their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.44.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $41.43 on Tuesday. Twist Bioscience has a fifty-two week low of $23.00 and a fifty-two week high of $60.90. The stock has a market capitalization of $2.43 billion, a PE ratio of -10.85 and a beta of 1.78. The business’s 50-day simple moving average is $43.98 and its 200-day simple moving average is $46.18.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the sale, the chief financial officer now directly owns 73,397 shares in the company, valued at $3,068,728.57. This represents a 1.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Chess sold 3,600 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $47.26, for a total value of $170,136.00. Following the completion of the transaction, the director now owns 21,641 shares of the company’s stock, valued at $1,022,753.66. This represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of TWST. ProShare Advisors LLC raised its position in Twist Bioscience by 10.2% in the first quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock valued at $496,000 after purchasing an additional 1,336 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Twist Bioscience by 14.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 18,649 shares of the company’s stock worth $640,000 after acquiring an additional 2,410 shares during the last quarter. Edgestream Partners L.P. bought a new position in shares of Twist Bioscience during the first quarter worth about $242,000. American International Group Inc. raised its position in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares during the last quarter. Finally, PEAK6 Investments LLC raised its position in shares of Twist Bioscience by 20.7% during the first quarter. PEAK6 Investments LLC now owns 14,000 shares of the company’s stock worth $480,000 after acquiring an additional 2,400 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.